DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

While we've known that a healthy diet reduces the overall chance of getting cancer, there's now evidence that one eating plan ...

Panelists discuss how multiple myeloma patients often navigate through numerous treatment regimens over their disease course, ...

Panelists discuss how multiple myeloma support resources range from formal organizations like the International Myeloma ...

Groundbreaking research at the Yale Cancer Center offered hope for patients diagnosed with Multiple Myeloma, a type of blood ...

Researchers sought to determine the significance of short-term blood pressure variability for assessing CTR-CVT in patients with multiple myeloma undergoing treatment with proteasome inhibitors.

Longtime 95.5 WSB radio host Scott Slade has announced he has been diagnosed with multiple myeloma, a type of blood cancer ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

"I decided to take charge of my own story. I shared my diagnosis with friends and colleagues. I did not want to hide the ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...